Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AIM ImmunoTech Inc.HEB · Entity 8131 | Chief Science/Medical Officer | June 21, 2019 | June 25, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AIM ImmunoTech Inc.
Report date June 21, 2019 · Filed June 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,420 |
Reported balance
After 2019-06-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-06-21 · Purchase · Acquired 2,481 · Balance 5,420 F1: Previous Balance of the amount of Securities Owned was divided by 44 due to the 44/1 stock split which occurred on June 11, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Previous Balance of the amount of Securities Owned was divided by 44 due to the 44/1 stock split which occurred on June 11, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2019 Filed Jun 25, 2019 15:40 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 2,481 | $4.03 | $9,998.43 |
DisclosureSEC source: 0001702626-19-000005 · primary_doc.xml · nonDerivative · entry 1 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,420 F1 · balance_after: Previous Balance of the amount of Securities Owned was divided by 44 due to the 44/1 stock split which occurred on June 11, 2019. Read SEC document |
| May 08, 2019 Filed Jun 17, 2019 18:58 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | ConversionCommon Stock | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001613377-19-000004 · primary_doc.xml · nonDerivative · entry 2 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Rights offering warrants using the cashless conversion feature, were converted into .70 number of shares. Read SEC document |
| March 25, 2019 Filed Jun 17, 2019 18:58 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | ConversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001613377-19-000004 · primary_doc.xml · nonDerivative · entry 1 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share has a stated value of $1,000 and was converted into 5,000 shares of Series B Common Stock for each of the ten shares issued. Read SEC document |
| March 04, 2019 Filed Mar 13, 2019 16:51 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherSubr Rights(to buy) · Derivative | 10 | $1,000.00 Strike: $1,000.00 | $10,000.00 |
DisclosureSEC source: 0001583701-19-000002 · primary_doc.xml · derivative · entry 3 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Pref Stk/Warrants · Not disclosed shares Expires 2019-03-05 F1 · derivative.underlying: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F2 · derivative.underlying: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F3 · derivative.underlying_shares: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 shares of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| March 04, 2019 Filed Mar 13, 2019 16:51 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherWarrants | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001583701-19-000002 · primary_doc.xml · nonDerivative · entry 2 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F2 · security: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F2 · shares: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F2 · price: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F3 · price: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 shares of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| March 04, 2019 Filed Mar 13, 2019 16:51 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherSeries B Convertible Preferred Stock | 10 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001583701-19-000002 · primary_doc.xml · nonDerivative · entry 1 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10 F1 · security: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F1 · shares: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F1 · price: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F3 · price: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 shares of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 16:36 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 184,659 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001450324-19-000005 · primary_doc.xml · derivative · entry 1 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,659 Underlying: Common Stock · 184,659 shares Expires 2029-01-28 F1 · security: This option is being issued to senior management for a voluntary 50% deferral in salary. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 15:11 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001613377-18-000035 · primary_doc.xml · nonDerivative · entry 1 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,304 F1 · kind: The Board of Directors awarded 2,500 shares of Company common stock to each employee, executive, and board member as a holiday bonus to be issued after January 2, 2019. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 16:55 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 1,000 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001613377-18-000031 · primary_doc.xml · derivative · entry 1 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2028-11-14 F1 · security: This option has been awarded by the Board of Directors. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 15:24 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 123,106 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001613377-18-000022 · primary_doc.xml · derivative · entry 1 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,106 Underlying: Common Stock · 123,106 shares Expires 2028-10-17 F1 · security: This option is being issued to senior management in exchange for a voluntary 50% deferral in salary. Read SEC document |
| April 12, 2018 Filed Apr 19, 2018 17:46 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 75,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001465652-18-000004 · primary_doc.xml · derivative · entry 1 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-04-12 F1 · security: This option is being awarded by the Board of Directors. Read SEC document |
| May 02, 2017 Filed May 2, 2017 18:31 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 7,937 | $0.63 | $5,000.31 |
DisclosureSEC source: 0001613377-17-000006 · primary_doc.xml · nonDerivative · entry 1 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,804 Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 19:15 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 9,892 | $0.46 | $4,550.32 |
DisclosureSEC source: 0001613377-17-000003 · primary_doc.xml · nonDerivative · entry 1 STRAYER DAVID R · CIK 0001270074 · Chief Science/Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,867 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.